We studied 81 children, mostly boys, who experience d language acqui sition delay but whose audiometric thr esholds were norm al. We assessed the evo lution of children with delayed maturation ofauditory pa thways by brainstein evoked respo nse audiome try (BERA) . We also used a questionnaire admin istered duri ng diagnostic p rocedu res to determin e if there was a probable etio logy in each pa tient. In addition, we f urthe r studied langua ge evo lution in 29 pati ents by means ofa second questionn aire that was administered approximately 2 years later. Finally, we studied the evo lution ofthe 1-Vinten vave interval and the IN amplitude ratio in 16 patients by p erformin g a second BERA aft er a mean inte rval of 3 years. We observed imp rov ement in both brainstem tran smission tim e and langua ge acqui siti on in all 81 patients. Ho wever, From the Discipline of Otolaryngology, Facu ldade de Medicin a da Unive rsidade de Mogi das Cruzes, Braz il (Dr. Fuess), and the
only a fe w patients achi eved normal rang e results. Morphologic alt erations, which were most common in patient s who had had p erinatal jaundice, remained unchange d. The most common p ossible risk factors for the delayed maturation pattern observed on BERA were parental consang uinity, prematurity, perinatal anoxia and j aundice, and postna tal se izure and infection. Som e patients had more than one ofthese p ossible risk f actors. We conclude that high-risk newborn s and 2-year-old children who ha ve no primitive verba l langua ge skills sho uld undergo BERA as well as in vestigation ofhearing thresholds, int en vave intervals, and IN amplitude ratios.
Introduction
During our 10 years ' experience with brain stem evoked response audiometry (BERA) in children, we have observe d a high incidence of length ening of the interval betw een wav es I and V in pati ents with suspec ted audiolog ic or neurologic disturb anc es. Thi s elong ation is probabl y attributable to a delay in matu ration of the auditory path way in the brainstem . These patients frequ ently exhibit language acquisition disturbances despite havin g norm al electrophysiolog ic thre sholds and an absence of motor or auditory lesion s; thi s disorder is more common among boys than girls.I
The primary acoustic nuclei of the brainstem (cochlear and oliv ar superior nuclei) are the fir st auditory relay stations to the more central regions, and they are responsible for comprehension of language symbols and reflex respon ses to sound. The ventral nucl eus exhibits reflex acoustic activity, whe reas the dorsal nucleus proc esses dyn ami c and complex auditor y stim uli and acts as a central integrator unde r the inhibitory influence of the ventral nucleus.' Along the course between the cochl ear nucle i and the olivary complex, auditory fibers fun ctionally inte ract with reti cul ar formation structures and form the nonspecific acoustic path way. The rostral portion of the reticul ar formation respond s to new acoustic stimuli, whereas the posterior porti on acts as a cere bra l modulator that synchronizes stimuli and functions.
Histologic studies of children with neonatal asphyxia have revealed the presenc e of brainstem lesion s in appro ximately 90 %. 3 The imm atu re reticular formation is particularly vulnerable to asphyxia.' Cell loss of the cochl ear nuclei , especially in the ventral nuclei, has also been observed in the se patients, as hav e minor changes in the olive, the superior olivary complex, and the inferior IN fROSIVf GfRO r ONCE-A-DAY A~I PHf X ®-24-nour acid control from tne first~ose Symptom relief on day 1*1 All-day, all-night acid control ' An excellent safety profile In clinical trials the most common side effect assessed as possibly related to ACIPHEX was headache (2.4% vs 1.6% for placebo) . Symptomatic response to therapydoes not preclude the presence of gastric malignancy. ACIPHEX is contraindicated in patients with known hypersensitivity to rabeprazole, substituted benzimidazoles, or to any component of the formulation. Patients treated with a proton pump inhibitor and warfarin concomitantlymayneed to be monitoredfor increases in INR and prothrombin time. In vitro incub ations emp loying human liver micro somes indicated that rabeprazole inhibited cyclosporine metabolism wi th an IC" of 62mlcrorno lar, a concentrationthat is over 50 times higher than the Cm " in healthy voluntee rs followi ng 14days of dosing with 20 mg of rabeprazole. This degree ofinhibition is similar to that byomeprazoleatequivalent concentrat ions. Rabeprazole produces sustained inhi bitionof gastric acid secretion. An interactionwith compounds which are dependent on gastric pH for abso rption may occur due to the magnitude of acid suppression obse rved with rabeprazole. For exam ple, in normal subjects, co-administration of rabeprazole 20 mg 00 resulted in an approximately 30% decrease in the bioavailab ility of ketoconazoleand increases in theAUC andCm " fordigoxin of 19% and 29%, respectively. Therefore, patients may need to be monitored when such drugs are taken concomitantly with rabeprazole. Co-administrat ion of raoeprazole and antacids produced no clinically relevant changes in plasma rabeprazoleconcentrations.
In a clinical study inJapan evaluating rabeprazol e in patients categorized byCYP2C19 genotype (n=6 per genotype category). gastric acid suppression was highe r in poor rnetaboszers as compared to extensive rnetabolizers. This could bedue to hi gher rabe prazole plasma levels in poor metabolizers. Whether or not interactions of rabeprazole sodium wi th other drugs metabolized byCYP2C19would be different bet weenextensive metabolizers and poor metabolizershas notbeen studied. Carcinogenesis, Mutagenesis, Impai rment ofFertility In a 88il04-week carcinogenicity study in CD-I mice, rabeprazole atoraldoses upto 100 mg/kg/day did not produce any increased tumor occurrence. The highest tested dose produced a system ic exposure to rabeprazole (AUC) of 1.40~g ' h r / mL which is 1.6times the human exposu re (plasma AUC Ooo = 0.88~g' hr / mL ) at the recommen ded dose for GERD (20 mg /day) . In a 104-week carcinogenicity study in Sprague-Dawley rats, males weretreated with oral doses of 5, 15, 30 and 60 mg/kg/day and females with 5, 15, 30, 60 and 120 mg/kg/day. Rabep razole produced gastric enterochromaffin-like (ECL) cell hyperplasi a in maleand female rats and ECL cell carcinoid tumors in female rats at alldoses including the lowest tested dose. The lowest dose (5 mg/kg/day) produced a systemic exposure to rabeprazole (AUC) of about 0.1~g ' hr / m L which is about 0.1 times the human exposu re at the recommended dose for GERD. In male rats, no treatment related tumors we re observed at doses up to 60 mg/kg/day producing a rabepraznl e plasma exposure (AUC) of about 0.2~g ' h r / m L (0.2times thehuman exposu reatthe recommended doseforGERD). Rabeprazole was positive in the Ames test, the Chinese hamster ovary cell (CHO/HGPRT) forward gene mutation test and the mouse lymphoma cell (L5178YITK+/-) forwa rd gene mutation test. Its demethylated-metabolitewas also positive in theAmes test. Habeprazolewas negative in the in vitro Chinese hamster lung cell chromosome aberration test, the in vivo mouse micronucleustest. and the in vivoand exvi vorat hepatocyte unscheduled DNAsynthesis (UDS) tests. Rabeprazole atintravenous doses up to 30 mg/kg/day (plasma AUCof 8.8~g ' hr / mL , about 10 times the human exposureat the recommended dose for GERD) was found to have noeffect onfertilityand reproductive performanceofmale and female rats. Pregnancy Teratogenic Efl ects. Pregnancy Category B Teratology studies have been performedin rats at intravenousdoses upto50mg/kg/day (plasmaAUC of 11. 8~g ' hr /m L , about 13 times the human exposu re at the recommended dose for GERD) and rabbits at intravenous doses up to 30 mgikg/day (plasma AUC of 7.3~g ' h r / mL , abou t 8 times the human exposure at the recommended dose for GERD) and have revealed no evidence of impaired ferti lity or harmto the fetus due to rabe prazole. There are, however, no adequate and wel l-controlled studies in pregnantwomen. Because animal reproduction studies are not al wayspredict ive of human response, this drugshould be used during pregnancy only if clearly needed. Nursing Mothers Foll owing intravenous administration of "C-Iabeled rabeprazole to lactating rats, radioactivity in milk reached levels that were 2-to Hold higher than levels in the blood. It is not known if un metabolized rabeprazole is excreted in human breast milk. Administration of rabeprazole to rats in late gestation and duringlactation atdoses of 400 mg/kg/day (about 195-times the human dose based on mg/m') resulted in decreases in body weigh t gain of the pups. Since many drugs are excreted in milk, and because of thepotential for adverse reactions to nur sing infants from rabeprazole, a decision should be made to discontinue nursingor discontinue the drug, taking into account the importance of the drug to themother. PediatricUse Thesafety and effectiveness of rabeprazolein pediatric patientshavenot been established. Use inWomen Duodenal ulcer and erosive esophagitis healing rates in women aresimilarto those in men. Adve rse events and laboratory test abnormalities inwomenoccurred atrates similar tothosein men. Geriatric Use Of the total number ofSUbjects inclinical studies ofACIPHEX' , 19%were65yearsand over, while4% were75yearsand over. Nooveralldifferences insafety oreffectiveness wereobserve d betweenthese subjects and younger subjects, and other reported clinical experie nce has not identified differences in responses between the elderly andyounger patients, but greatersensitivity of some ol der individuals cannot be ruled out. ADVERSE REACTIONS Worldwide, ove r 2900 patients have bee n treated with rabep razole in Phase II-III clinical trials involving various dosages and durations oftreatment. Ingeneral, rabeprazoletreatment has been welltolerated in both short-term and long-term trials. The adverse events rates were generally similar betweenthe 10 and 20mg doses.
Incidence in Controlled North American and European Clinical Trials
In an analysis of adverse eventsassessed aspossibly or probably related to treatment appearingin greater than 1%of ACIPHEX' patients and appearingwithgreater freq uency than placeboincontrolled North American and European trial s, the incidence of headache was 2.4% (n=1552) for ACIPHEX' versus1.6%(n=258) for placebo.
In short and long-term studies, thefollowing adverse events, regardless of causality, werereported in AC I P H EX~-t reate d patien ts. Rare eventsare thosereportedin~1 / 1 000patients. co llic ulus ." Howev e r. it is bel ieved tha t perina ta l a nox ia ca n ser io us ly damage no t o n ly pure -ton e aud itory fun ction but al so mor e co m ple x ac ti vi t)' . suc h as spee c h inte rpretati on . T he lat en cy o f wave I o n S E RA pro gr essi vel y d imi nishes between b irt h and 8 to 10 wee ks fo llo wi ng dc liver y ."!> Late r. a seco nd -phase aud itor y func tio n maturat ion occ urs . whi ch involves a s lower rat e of decrease of later wave lat en c ie s. pa rtic ula rly of wave V.,·7 It is not un til c h ild re n reac h ap proxi mate ly 2 years a nd 6 mo nt hs o f age tha t the ir aco us tic in forma t io n process ing becomes s imilar to th at se e n in ad ults. T he yo unge r the c hi ld is . the g re ate r th e lat en c y o f the wa ve s is in eac h test ed ton e inten sity.
So me a uth ors beli e ve th at in patie nts w ith pe rinat a l hy po x ic e nce pha lopathy . the ede ma m ight inte rfe re w ith sy na ptic tra ns m ission. Th ey feel that th is int erfe ren ce mi ght lead to a n increase in wave V la ten cy o n SE RA as a resu lt o f ( I ) the increase in the size of the intrace llular spaces and (2) ce ll lo ss in the a rea of the coch lea r nucl e i. U po n redu ct ion o f the ede ma. S ER A results m ight impro ve if the re has bee n no per ma ne nt d am age to neural tissu c.s" A fe w prosp ecti ve stud ies of ne wb orn s a t h ig h risk for dev e loping neuro log ic di sturban ces w ho we re fo llowe d until they re ach ed sc hoo l ag e sho we d a high incide nce of la ng uage a nd lea rni ng defi c ien ci e s as an ex press io n of sub tle neu rol og ic seque lae .'"
In v iew of the fac t th at patie nts diagnosed wi th delayed ma tu ration of the aud itory pa thway w ho experie nce delayed la ng uage acq uis ition b ut w ho have norma l a ud itor y thr esh old s a rc ge ne ra lly co ns ide red to ha ve a good progno sis. we beli e ve th at they usu all y rece ive less att e ntion than they sho uld fro m ph ysici an s a nd psyc ho log ists. Becau se we found no dat a in th e liter ature re garding the e vo lutio n o f these c h ild re n. we co nce ive d thi s study to a na lyze the se cases. O ur study had fou r primary goa ls: Group II . Grou p II was mad e up of the 24 patie nts w ho se g uardians d id no t answe r the seco nd qu esti onna ire .
Resu lts
In itial assessment. We rev ie we d the re sp on ses to the 12 (14 .8) initia l 8 1 questionn aires (table) and the res ults of the first BERA exa mination. BE RA curves showed signs of delayed maturation of the aud itory path way (enlarge me nt of the interval I-V) in 79 of the 8 1 pat ients and a dis proportionate wave I am plitude in the other two (w ho were given a diagnos is of a diff use bra ins tem lesion)." Th e BERA analysis revea led that the electrophysio logic thresho ld was between 20 and 30 dB in 52 patient s (64.2 %), 40 dB in 12 patient s (14 .8%), and betwee n 50 and 60 dB in [7 pat ients (2 1.0%). Latency intervals ra nged from 4.0 to 5.7 msec (mean: 4.76 .± 0.23) in a norm al distribution pattern . On ly one pat ient ex hibited a mo rpholog ic change in wave V; the wave I amp litude was larger than the wave V amp litude in 12 patients, with or withou t elongation of the 1-V latency intervals.
Second assessm ent: Group I. Amo ng the 29 patient s whose guardia ns completed the second ques tionnaire (group I), 12 (4 1.4%) had a richer vocabulary, whi le eight (27 .6%) cont inued to be unable to speak or to ex hib it only rudimentary lan guage. A compariso n ofspoken language evo lutio n between the first and second questionnaires is show n in figure I. Mo reover, 24 of the 29 childre n (82.8 %) were und ergoing phonotherapy, with or wit hout psychoth erapy. Ana lys is of beha vior showed that with the exception of one isol ated case of severe neu ropsychomotor developme nt delay and one case of suspected autism , all chil dre n were co nside red to be norm al by their guardians in terms of showi ng affectio n. So me children we re co nsidered to be "excited," but no ne was agg ressive. Overall, their verbal co mpre hension was goo d, altho ugh gua rdia ns men tioned that so me chi ldre n co nfused wor ds tha t we re si milar or had some difficulty learnin g the na mes of the co lors. 
Discussion
As is the case with all studies that are based on surveys, questions arise as to how representative and valid our findings are. In analyzing the data on age, neuropsychomotor development, language acquisition, and hearing acuity provided by the guardians during the first questionnaire and BERA assessment, we did not find any differences that would suggest that there was any specific reason that the 29 guardians in group I were more interested than those in group II in answering the second questionnaire. Likewise, we did not find any specific reason why the guardians of the 16 patients in subgroup IA were more motivated to have their children undergo the second SERA examination than were those in subgroup lB . In analyzing the changes we observed in BERA results, neuropsychomotor development, and language development patterns, we considered their relationships to several pre-, peri-, and postnatal factors, but it was still difficult to isolate simple cau se-and-effect associations. " The most common possible risk factors were perinatal anoxia (n = 19), postnatal seizures (n =7), postnatal infection (n =6), perinatal jaundice (n =5), prematurity (n =5), and parental con sanguinity (n = 5) . Some patients had more than one of these possible risk factors.
Four of the five patients with perinatal jaundice exhibited a significantly greater increase in the amplitude of wave I than in the amplitude of wave V. This finding is in agreement with that of Lenhardt et ai, who reported that hyperbilirubinemia can lead to an increase in axon degen- eration and a grea ter loss of myelin than of ciliated cell s. 14 None of the nine patient s whose wav e I amplitude was greater than the wave V amplitude demonstrated normalizat ion of the I-V interval on the seco nd BER A. Jiang observe d that after asphy xiation , prolonged I-V intervals return ed to norm al more quickl y than did reduc ed wave V amplitudes and decr eased I/V amplitude ratios ." Even thou gh our patient s had been exa mined durin g their childh ood rath er than during their neon atal period , they showed improvement in their BERA result s. Knowing that clinical imp rovement in these patient s can be slow, all possibl e therapies should be offered so that their impro vement can take place as rapidly as possible . Because it is not possible to det ermine whether any specific child will or will not improve, it is worth administerin g stimulation ther apy to all children as soon as possible.' Newborn s who are con sidered to be at risk for hearin g loss must undergo BERA testing to ascertain their aud itory threshold, I-V latency interval, and IN amplitude ratio ." If these param eters indic ate any change, the patient' s development pattern and BERA result s shou ld
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For Oral Boards be carefully observed becau se the verbal langu age acquisition pattern in these patient s is often compromised. Any child who has not acquired at least rudim entary verbal langua ge skills by the age of 2 year s should underg o BER A testing . An incre ase in the I-V latency inter val requires that these patient s und ergo neurologic , phoniatric, and psychological evaluations so that any stimulation therapy can be started as soon as possibl e. In patients who exhibit an increase in wave I amplitude and/or any morphologic change in wave V, care must be inten sified bec ause brain stem anomalies in these patients tend not to resolve.
